Market Cap 307.48M
Revenue (ttm) 213.65M
Net Income (ttm) -38.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -18.16%
Debt to Equity Ratio 0.00
Volume 55,900
Avg Vol 66,760
Day's Range N/A - N/A
Shares Out 20.80M
Stochastic %K 27%
Beta 0.81
Analysts Hold
Price Target $12.00

Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 353 0 166 99020
Address:
One Central Plaza, 8th Floor 36 Dame Street, Dublin, Ireland
DoMoreCharity
DoMoreCharity May. 16 at 3:05 AM
$AMRN https://www.hoganlovells.com/en/publications/jpm-2026-fda-panelists-prioritize-faster-approvals-national-security-ai-and-more
0 · Reply
Theobviouschoice
Theobviouschoice May. 16 at 1:02 AM
$CAPR Oh no Karim Mikhail - this guy did a terrible job managing $AMRN now his the head of the FDA. Anyone in $AMRN care to validate if I got this wrong 🤯
3 · Reply
DoMoreCharity
DoMoreCharity May. 15 at 11:56 PM
$AMRN https://www.nasdaq.com/market-activity/stocks/amrn/institutional-holdings?page=1&rows_per_page=10
0 · Reply
HostmanG
HostmanG May. 15 at 5:06 PM
$AMRN How about throwing us long dedicated & suffering shareholders a bone by providing us a $1-2 dividend?
2 · Reply
revivedfossil
revivedfossil May. 15 at 4:56 PM
$AMRN low volume shenanigans
0 · Reply
NotAgain2024
NotAgain2024 May. 15 at 3:35 PM
$AMRN just a bunch of losers that work at amarin
0 · Reply
Ilikebeinggreen
Ilikebeinggreen May. 15 at 3:12 PM
$AMRN The talent at this company is mediocre. It is a B team at best. There is no reason to keep providing them with additional "bonuses." They have enough incentive from previous years to sell the company. That should be their only motivation. Anything beyond that is unnecessary. The company performance has sucked, so no more bonuses.
0 · Reply
Ilikebeinggreen
Ilikebeinggreen May. 15 at 3:04 PM
$AMRN Preventing further dilution on the sly is a good thing. Since mgmt's compensation upside is already tied largely to stock, they will be careful about reducing cash on hand too much. Everyone will notice, and that's the only asset that is currently being valued by the market. If they crash the stock by being overtly greedy, it will more than offset the value of their cash payouts. The "talent" at this company is largely mediocre and disposable. They'll hang around. Mgmt and Board are already deeply invested, so you don't need to overpay. The dilution was a slick greedy move -- and unnecessary. The light will be shining bright on what they do with cash reserves, so I don't think they will fiddle with it too much. Sell the damn company already. That's how you'll get a meaningful bonus.
0 · Reply
Guddler
Guddler May. 15 at 12:05 PM
$AMRN maybe the directors and management will use the extra cash to buy shares on the open market. 🤔 🫣.
2 · Reply
crayonboy
crayonboy May. 15 at 11:32 AM
$AMRN so cash on hand will be diluted but not shares. What’s better in the long term or does it matter? Any thoughts as to why you support one or the either?
1 · Reply
Latest News on AMRN
Amarin Reports 2026 First Quarter Financial Results

Apr 29, 2026, 7:00 AM EDT - 16 days ago

Amarin Reports 2026 First Quarter Financial Results


Amarin highlights new recommendation for treatment of CV risk

2026-03-18T12:41:54.000Z - 2 months ago

Amarin highlights new recommendation for treatment of CV risk


Amarin highlights recent data published on REDUCE-IT study

2026-03-02T13:26:30.000Z - 2 months ago

Amarin highlights recent data published on REDUCE-IT study


Amarin issues call to action for American Heart Month

2026-02-23T13:23:34.000Z - 2 months ago

Amarin issues call to action for American Heart Month


Amarin expects Q4 net revenue $48M-$43M

2026-01-08T12:06:26.000Z - 4 months ago

Amarin expects Q4 net revenue $48M-$43M


Amarin reports Q3 EPS (2c) vs (6c) last year

2025-10-29T11:11:18.000Z - 7 months ago

Amarin reports Q3 EPS (2c) vs (6c) last year


Amarin presents new REDUCE-IT analyses

2025-09-01T12:30:11.000Z - 9 months ago

Amarin presents new REDUCE-IT analyses


Amarin announces upcoming presentations at ESC Congress 2025

2025-08-25T12:05:06.000Z - 9 months ago

Amarin announces upcoming presentations at ESC Congress 2025


Amarin expects accelerated in-market demand in Europe

2025-07-30T11:11:52.000Z - 10 months ago

Amarin expects accelerated in-market demand in Europe


Amarin Reports Second Quarter 2025 Financial Results

Jul 30, 2025, 7:00 AM EDT - 10 months ago

Amarin Reports Second Quarter 2025 Financial Results


Amarin regains compliance with Nasdaq

2025-04-29T20:40:18.000Z - 1 year ago

Amarin regains compliance with Nasdaq


Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change


Amarin Receives National Reimbursement for VAZKEPA® in Italy

Dec 16, 2024, 7:00 AM EST - 1 year ago

Amarin Receives National Reimbursement for VAZKEPA® in Italy


Amarin Appoints Peter Fishman Chief Financial Officer

Dec 13, 2024, 9:00 AM EST - 1 year ago

Amarin Appoints Peter Fishman Chief Financial Officer


Amarin Board of Directors Announces CEO Transition

Jun 4, 2024, 7:30 AM EDT - 2 years ago

Amarin Board of Directors Announces CEO Transition


Amarin Chairman & CEO Issue Letter to Shareholders

Jan 22, 2024, 7:30 AM EST - 2 years ago

Amarin Chairman & CEO Issue Letter to Shareholders


Amarin Reports Third Quarter 2023 Financial Results

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Amarin Reports Third Quarter 2023 Financial Results


DoMoreCharity
DoMoreCharity May. 16 at 3:05 AM
$AMRN https://www.hoganlovells.com/en/publications/jpm-2026-fda-panelists-prioritize-faster-approvals-national-security-ai-and-more
0 · Reply
Theobviouschoice
Theobviouschoice May. 16 at 1:02 AM
$CAPR Oh no Karim Mikhail - this guy did a terrible job managing $AMRN now his the head of the FDA. Anyone in $AMRN care to validate if I got this wrong 🤯
3 · Reply
DoMoreCharity
DoMoreCharity May. 15 at 11:56 PM
$AMRN https://www.nasdaq.com/market-activity/stocks/amrn/institutional-holdings?page=1&rows_per_page=10
0 · Reply
HostmanG
HostmanG May. 15 at 5:06 PM
$AMRN How about throwing us long dedicated & suffering shareholders a bone by providing us a $1-2 dividend?
2 · Reply
revivedfossil
revivedfossil May. 15 at 4:56 PM
$AMRN low volume shenanigans
0 · Reply
NotAgain2024
NotAgain2024 May. 15 at 3:35 PM
$AMRN just a bunch of losers that work at amarin
0 · Reply
Ilikebeinggreen
Ilikebeinggreen May. 15 at 3:12 PM
$AMRN The talent at this company is mediocre. It is a B team at best. There is no reason to keep providing them with additional "bonuses." They have enough incentive from previous years to sell the company. That should be their only motivation. Anything beyond that is unnecessary. The company performance has sucked, so no more bonuses.
0 · Reply
Ilikebeinggreen
Ilikebeinggreen May. 15 at 3:04 PM
$AMRN Preventing further dilution on the sly is a good thing. Since mgmt's compensation upside is already tied largely to stock, they will be careful about reducing cash on hand too much. Everyone will notice, and that's the only asset that is currently being valued by the market. If they crash the stock by being overtly greedy, it will more than offset the value of their cash payouts. The "talent" at this company is largely mediocre and disposable. They'll hang around. Mgmt and Board are already deeply invested, so you don't need to overpay. The dilution was a slick greedy move -- and unnecessary. The light will be shining bright on what they do with cash reserves, so I don't think they will fiddle with it too much. Sell the damn company already. That's how you'll get a meaningful bonus.
0 · Reply
Guddler
Guddler May. 15 at 12:05 PM
$AMRN maybe the directors and management will use the extra cash to buy shares on the open market. 🤔 🫣.
2 · Reply
crayonboy
crayonboy May. 15 at 11:32 AM
$AMRN so cash on hand will be diluted but not shares. What’s better in the long term or does it matter? Any thoughts as to why you support one or the either?
1 · Reply
DoMoreCharity
DoMoreCharity May. 15 at 10:53 AM
$AMRN https://www.sec.gov/ix?doc=/Archives/edgar/data/0000897448/000119312526224771/amrn-20260513.htm
0 · Reply
BobGood
BobGood May. 15 at 10:50 AM
$AMRN Hi Guys Didn’t happen what’s expected!! All existing directors re-elected 😡 E& Y re-elected as expected All points voted “For” except Item 10, 11 & 12 voted against Good thing is outstanding shares wouldn’t be diluted further .. But COH will be diluted God bless Amarin GL
0 · Reply
invest2992
invest2992 May. 15 at 10:48 AM
$AMRN 8k, another rape Job?
0 · Reply
focafoca99
focafoca99 May. 15 at 10:20 AM
$AMRN declared several shareholder proposals were rejected at its annual meeting, curbing its ability to issue shares and prompting https://www.rapidticker.com/news/amrn-sec-filing-d234b1
0 · Reply
NotAgain2024
NotAgain2024 May. 15 at 7:33 AM
$AMRN get ready for more nothing burger till june
0 · Reply
DoMoreCharity
DoMoreCharity May. 15 at 2:13 AM
$AMRN Secondary Prevention After Coronary Artery Bypass Graft Surgery: 2026 Update: A Scientific Statement From the American Heart Association Originally Published 13 May 2026 https://www.ahajournals.org/doi/10.1161/CIR.0000000000001434
0 · Reply
Md80dog
Md80dog May. 14 at 9:52 PM
$AMRN Get ready for Supreme Court ruling
0 · Reply
Noche
Noche May. 14 at 7:32 PM
$AMRN Get ready for a Friday night news drop on the shareholders meeting.
1 · Reply
BobGood
BobGood May. 14 at 6:35 PM
$AMRN IMHO majority of the shareholders must have voted “against” for re-election of any of the existing directors … Under such conditions, I don’t know what will be the next step from legal aspects… may be this’ll be best time to sell the company …. GL
1 · Reply
Family23
Family23 May. 14 at 5:57 PM
$AMRN per SDL recent post, this doesn’t sound like a BO is anywhere near close. Why mention Q3 figures if BO was happening before hand. His BO target is 🤡
1 · Reply
NotAgain2024
NotAgain2024 May. 14 at 4:41 PM
$AMRN a lot of du people here
2 · Reply
MoneyInc
MoneyInc May. 14 at 2:11 PM
Nice! I’m also in GAUZY for a swing over $3 I think it’s coming soon. Tzoo could be triple digits this time next year!! My other big position is $GALT .. let’s see a surprise but deserved approval in the next few months and $50+ $AMRN $GAUZ $REFR $TZOO
0 · Reply